Advisory Board

The Veratrak Advisory Board is made up of individuals with deep expertise and experience across Pharmaceuticals, Supply Chain, Manufacturing, Packaging, Digital, and Technology. They advise and guide Veratrak as we improve collaboration across the pharmaceutical supply chain.

Charles Songhurst

Charles is a consummate insider in the tech scene and a leading technology investor. He previously worked at Microsoft as head of Global strategy, reporting directly to the CEO. Charlie directed the acquisition of both Yahoo and Skype and, alongside Bill Gates, negotiated Microsoft’s entry into Facebook. Charles now manages his own VC which has large stakes in the quantum computing, biotech, space and enterprise SaaS industries.

Dr. Heinrich Zetlmayer

Heinrich Zetlmayer, General Partner at Blockchain Valley Ventures, is an accomplished digital investor and board member. With more than 20 years experience in Supply Chain Management and Operations, Heinrich was a VP at IBM's Global Business Services leading Supply Chain and Operations Management Services in EMEA.

Tony Fitzpatrick

Tony brings over 30 years of strategic, supply chain, and operations experience in the logistics, pharmaceutical and medical device industries. Currently, Tony is EVP Operations at Vectura Group, and previously worked at Baxter for 18 years including serving as VP Global Supply Chain, and VP Operations EMEA.

David Buller

David Buller is an entrepreneur, angel investor, CEO at Buller Invest, and Venture Partner at Ascension Ventures. An entrepreneur since the age of 15, David founded Avantec (hospital supplies and pharmacy automation), which was acquired by Omnicell in 2015. He works with investors, syndicates, VCs, accelerators and startups in the UK, Europe and USA as a startup advisor and mentor, supporting startups raise capital and investors find funds and deal-flow.

Antonin de Fougerolles

Antonin de Fougerolles is the CEO of Evox Therapeutics and a Venture Partner at Ascension Ventures with over 20 years’ experience in the pharmaceutical and biotechnology industry. He has a background in developing transformative therapeutic drug platforms in the nucleic acid and biologics space. His expertise has led to the progression of multiple assets through clinical trials. Prior to joining Evox Therapeutics, Tony was CSO at Ablynx NV and Moderna Therapeutics, and VP Research at Alnylam Pharmaceuticals. He holds a PhD in Immunology from Harvard University.

Agash Navaranjan

Agash Navaranjan is an experienced technologist in the Blockchain space. Currently the CTO of DoveTail Lab working on creating audit trails for medical data transfer. Previously Agash ran a Blockchain consultancy working with clients such as HSBC, Rabo Bank and various startups working with using Ethereum and Hyperledger Fabric.

Dexter Tjoa

Dexter is an experienced senior executive in the pharmaceutical industry. Currently, he is Director Corporate Strategy at Tjoapack, a leading pharmaceutical contract services organisation, reporting directly to the CEO. He is responsible for business strategy and growth of the company. Dexter brings supply chain, commercial, and technology expertise with a track record of leading large innovation and change projects. He holds an MSc in mathematics and computer science from the University of Oxford and has previously worked in technology sector.

David Evans

David is a highly driven and energetic leader, with over 30 years of experience in the deployment of innovative and sustainable solutions for the pharmaceutical sector. David has previously worked as Head of End to End Supply Chain Design at Merck, and as a Global Strategy and Innovation Director of GSK. David brings an extensive track record of leading major initiatives, including systems deployment projects, restructuring organisational functions, strategy development and deployment.

Dr. Mike Bogetofte Barnkob

Mike is a clinical doctor utilizing cellular therapies to combat cancer. He has 10 years of experience in tumour-immunology and is extensively involved in establishing a pipeline for delivering advanced therapy medicinal products in the Netherlands. He has received several awards, including the Ita Askonas medal. Mike completed his medical degree at Odense University Hospital, studied at Massachusetts Institute of Technology and holds a PhD in medical sciences from the University of Oxford.

Professor Richard W. Barker

Richard is Founding Director of New Medicine Partners and chairman of the South London Health Innovation Network. He also chairs Metadvice, and is a board member of Image Analysis, and of Celgene. He founded the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI). The senior roles he previously held include: Director General of the Association of the British Pharmaceutical Industry, GM of Healthcare Solutions for IBM, CEO of Chiron Diagnostics and head of McKinsey's European healthcare practice.

Stephen Allott

Stephen is a Venture Partner at Seedcamp, author of Sales Tales and is the Founder of the Cambridge University Computer Lab Ring. Stephen was President, CFO and a main board director of Micromuse (NASDAQ: MUSE). Reaching $7 billion market cap, MUSE is the most valuable organically grown UK origin software company to date. He has worked for Xerox, Sun Microsystems, McKinsey & Company, Red Gate Software and the Cabinet Office growing the G-Cloud Digital Marketplace to over £6 billion in sales.

Lindon Potter

Lindon has 10 years of experience in the pharmaceutical and healthcare sectors, including seven years of experience in quality assurance (QA), where he specialises in providing support associated with clinical trial conduct, medicinal product manufacturing, medicinal product distribution and pharmacovigilance. Lindon has held QA positions with various organisations including contract research organizations and pharmaceutical companies. Lindon has been operating as an independent consultant since 2017 providing GCP, GPvP, GDP and GMP QA and regulatory compliance services to customers.